Insights : sector - Osborne Clarke

Life Sciences and Healthcare

Learn more about this sector

Article list

Life Sciences and Healthcare

'Killer acquisitions' in Europe's pharmaceutical sector: is more regulation needed?

Competition authorities are increasingly focused on the impact of transactions on innovation in the life sciences and healthcare sector.

18/12/2024

Read time 5m

Life Sciences and Healthcare

Belgium creates a new legal exemption for unauthorised medicines

A novel form of 'named patient use' mechanism is meant to address special pharma needs and drug shortages

11/12/2024

Read time 4m

Artificial intelligence

How medical technology is navigating the AI Act in Europe

AI is transforming medical products and manufacturing as regulators look to keep pace with developments.

09/12/2024

Read time 1m

Life Sciences and Healthcare

Is the MHRA creating the right conditions to encourage UK investment in AI products?

Businesses bringing AI to market need to be aware of public policy and commercial factors driving regulatory reform

29/11/2024

Read time 8m

Life Sciences and Healthcare

EU enforces stricter liability for life sciences products

Pharma and medtech companies face enhanced liability under the EU's new directive

26/11/2024

Read time 4m

Tax

Spanish Supreme Court clarifies the binding nature of the report of the Ministry of Science and Innovation in order to apply tax deduction for technological innovation

Spanish Supreme Court annuls National High Court decisions regarding tax deduction for technological innovation

26/11/2024

Read time 3m

Life Sciences and Healthcare

Medtech sector faces new EU 'green deal' recommendations

Greener medical devices and processes are among MedTech Europe's recommendations for business sustainability

19/11/2024

Read time 5m

Life Sciences and Healthcare

Investment control in transactions in the life sciences and healthcare sector

Investment control means that additional regulatory approvals are required, affecting the timeline, complexity and costs of a transaction

18/11/2024

Read time 2m

Life Sciences and Healthcare

Life sciences dealmakers need to anticipate sector-specific factors in European M&A

European regulatory and intellectual property complexities must be addressed when engaging in mergers and acquisitions

15/11/2024

Read time 5m

Life Sciences and Healthcare

UK government to refresh post-market surveillance requirements for medical devices

New regulations introduced to bring the UK regulatory framework closer in line with international best practice for post-market surveillance requirements

08/11/2024

Read time 3m

The UK Budget

What do venture capitalists need to know about the UK government's policies?

Tax changes and growth plans pose opportunities and challenges for the venture capital community

07/11/2024

Read time 4m

Regulatory and compliance

What can UK business expect from regulators in future?

What can be learnt from the UK government's stated approach to regulation and growth?

07/11/2024

Read time 9m

The UK Budget

How does the UK Budget impact the life sciences and healthcare sector?

Change is afoot as more NHS investment and reforms follow a new industrial strategy and Regulatory Innovation Office

01/11/2024

Read time 4m

Life Sciences and Healthcare

EU tightens health tech regulations on supply chain disruptions

European Commission clarifies new rules for 2025, mandating early notification of potential medical device supply issues

31/10/2024

Read time 4m

Life Sciences and Healthcare

European Parliament urges revision of medical devices regulations

EU medtech and diagnostics sectors face critical regulatory updates in new parliamentary resolution

29/10/2024

Read time 4m

View all insights

Life Sciences and Healthcare

'Killer acquisitions' in Europe's pharmaceutical sector: is more regulation needed?

Competition authorities are increasingly focused on the impact of transactions on innovation in the life sciences and healthcare sector.

18/12/2024

Read time 5m

Life Sciences and Healthcare

Belgium creates a new legal exemption for unauthorised medicines

A novel form of 'named patient use' mechanism is meant to address special pharma needs and drug shortages

11/12/2024

Read time 4m

Artificial intelligence

How medical technology is navigating the AI Act in Europe

AI is transforming medical products and manufacturing as regulators look to keep pace with developments.

09/12/2024

Read time 1m

Life Sciences and Healthcare

Is the MHRA creating the right conditions to encourage UK investment in AI products?

Businesses bringing AI to market need to be aware of public policy and commercial factors driving regulatory reform

29/11/2024

Read time 8m

Life Sciences and Healthcare

EU enforces stricter liability for life sciences products

Pharma and medtech companies face enhanced liability under the EU's new directive

26/11/2024

Read time 4m

Tax

Spanish Supreme Court clarifies the binding nature of the report of the Ministry of Science and Innovation in order to apply tax deduction for technological innovation

Spanish Supreme Court annuls National High Court decisions regarding tax deduction for technological innovation

26/11/2024

Read time 3m

Life Sciences and Healthcare

Medtech sector faces new EU 'green deal' recommendations

Greener medical devices and processes are among MedTech Europe's recommendations for business sustainability

19/11/2024

Read time 5m

Life Sciences and Healthcare

Investment control in transactions in the life sciences and healthcare sector

Investment control means that additional regulatory approvals are required, affecting the timeline, complexity and costs of a transaction

18/11/2024

Read time 2m

Life Sciences and Healthcare

Life sciences dealmakers need to anticipate sector-specific factors in European M&A

European regulatory and intellectual property complexities must be addressed when engaging in mergers and acquisitions

15/11/2024

Read time 5m

Life Sciences and Healthcare

UK government to refresh post-market surveillance requirements for medical devices

New regulations introduced to bring the UK regulatory framework closer in line with international best practice for post-market surveillance requirements

08/11/2024

Read time 3m

The UK Budget

What do venture capitalists need to know about the UK government's policies?

Tax changes and growth plans pose opportunities and challenges for the venture capital community

07/11/2024

Read time 4m

Regulatory and compliance

What can UK business expect from regulators in future?

What can be learnt from the UK government's stated approach to regulation and growth?

07/11/2024

Read time 9m

The UK Budget

How does the UK Budget impact the life sciences and healthcare sector?

Change is afoot as more NHS investment and reforms follow a new industrial strategy and Regulatory Innovation Office

01/11/2024

Read time 4m

Life Sciences and Healthcare

EU tightens health tech regulations on supply chain disruptions

European Commission clarifies new rules for 2025, mandating early notification of potential medical device supply issues

31/10/2024

Read time 4m

Life Sciences and Healthcare

European Parliament urges revision of medical devices regulations

EU medtech and diagnostics sectors face critical regulatory updates in new parliamentary resolution

29/10/2024

Read time 4m

View all insights

Will James

Partner, International Life Sciences and Healthcare Sector Leader, UK

+44 207 105 7774 Email Will Full biog

Silvia Steiner

Partner, Spain

+34 93 419 18 18 Email Silvia Full biog

Dr Tim Reinhard

Partner, Wirtschaftsmediator (MuCDR), Germany

+49 89 5434 8024 Email Tim Full biog

Thomas Devred

Partner, Head of Life Sciences and Healthcare - Paris, France

+ 33 1 84 82 41 06 Email Thomas Full biog

Maria Grazia Medici

Partner, Head of Life Sciences & Healthcare, Italy

+39 06 3269 5015 Email Maria Grazia Full biog

Herke van Hulst

Partner, Advocaat, The Netherlands

+31 207 02 86 72 Email Herke Full biog

Catherine Wolfenden

Partner, Disputes & Risk Practice Group Head, UK

+44 117 917 3600 Email Catherine Full biog

Matthew Edwards

Partner, UK

+44 207 105 7786 Email Matthew Full biog

Marcus Vass

Partner, Head of Digital Health, UK

UK +44 2071 057 634 Email Marcus Full biog

Rafael García del Poyo

Partner, Spain

+34 91 576 44 76 Email Rafael Full biog

Peter Rudd-Clarke

Partner, UK

+44 207 105 7315 Email Peter Full biog

Tim Harris

Partner, UK

+44 207 105 7144 Email Tim Full biog

Giulia Verusio

Senior Associate, Italy

+39 06 3269 5008 Email Giulia Full biog

J. Carlos Suarez

Counsel, Italy

+39 02 5413 1772 Email J. Carlos Full biog

David Haex

Co-Managing Partner, Belgium

+32 2 515 9322 Email David Full biog

Xavier Pican

Partner, IP/ IT, France

+33 1 84 82 45 88 Email Xavier Full biog

Dr. Andrea Schmoll

Partner, Germany

+49 221 5108 4260 Email Andrea Full biog

Dr Flemming Moos

Partner, Specialist lawyer for IT law, Germany

+49 40 55436 4054 Email Flemming Full biog

Dr Martin Sundermann

Partner, Wirtschaftsmediator (MuCDR), Germany

+49 89 5434 8026 Email Martin Full biog

Marie-Louise Weeda

Partner, Lawyer, The Netherlands

+31 207 02 86 98 Email Marie-Louise Full biog

Steve Wilson

Managing Partner, US

+1 917 545 3672 Email Steve Full biog

Jordi Casas

Co-Managing Partner, Spain

+34 93 419 18 18 Email Jordi Full biog

Julia Kaufmann, LL.M.

Partner, Germany

+49 89 5434 8068 Email Julia Full biog

View all

Belgium

China

France

Germany

India

Italy

Poland

Singapore

Spain

Sweden

The Netherlands

UK

USA

Insights

Life Sciences and Healthcare

Article list

Connect with one of our experts

Sign up for our newsletter

Legal Notice